Print

AVEG 005C

A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of ENV 2-3 in Combination with MF59

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) October 30, 1991
Env 2-3 Env gp130 B SF-2
Env 2-3 Protein
MF59
USA 14
NCT00000632
http://clinicaltrials.gov/ct2/show/NCT00000632